vulgatus shrank. This, in turn, decreased the release of a hormone called FGF21, which is tied to sugar cravings. In studies of mice taking GLP-1 agonists, researchers have found the drugs ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Some companies claim that taking beneficial bacteria can reduce the desire for sugar. But the evidence comes from mice, not people.

Boehringer Ingelheim GmbH terminated its second metabolic dysfunction-associated steatohepatitis (MASH) alliance on March 6, ending an $870 million license agreement inked with Yuhan Corp. for dual ...

Importantly, FGF19 and FGF21 are essential targets for drugs that ... used the recombinant human GLP-1 receptor protein from Sino Biological (Cat#: 13944-H02H) to discover and characterize ...

they could potentially reduce the overall patient population eligible for FGF21 analog treatments. If GLP-1 therapies prove effective in preventing or slowing the progression of MASH in earlier ...